Deconex Tablet
NDC Package 50991-740-01
Package Information
Deconex (dextromethorphan hydrobromide, guaifenesin, phenylephrine hydrochloride) tablets is do not exceed recommended dosage.Adults and children 12 years of age and over: 1 tablet every 4 hours, not to exceed 6 tablets in 24 hours Children 6 to under 12 years of age: 1/2 tablet every 4 hours, not to exceed 3 tablets in 24 hours Children under 6 years of age: Consult a physician. This formulation utilizes a tablet delivery system. Marketed by Poly Pharmaceuticals, Inc., this product is identified by NDC 50991-740 and is authorized under FDA application M012.
Identification & Billing
- RxCUI: 2172190 - dextromethorphan HBr 17.5 MG / guaiFENesin 400 MG / phenylephrine HCl 10 MG Oral Tablet
- RxCUI: 2172190 - dextromethorphan hydrobromide 17.5 MG / guaifenesin 400 MG / phenylephrine hydrochloride 10 MG Oral Tablet
- RxCUI: 2172190 - dextromethorphan HBr 17.5 MG / guaifenesin 400 MG / phenylephrine HCl 10 MG Oral Tablet
Clinical Specifications
- Adrenergic alpha1-Agonists - [MoA] (Mechanism of Action)
- Decreased Respiratory Secretion Viscosity - [PE] (Physiologic Effect)
- Expectorant - [EPC] (Established Pharmacologic Class)
- Increased Respiratory Secretions - [PE] (Physiologic Effect)
- Sigma-1 Agonist - [EPC] (Established Pharmacologic Class)
- Sigma-1 Receptor Agonists - [MoA] (Mechanism of Action)
- Uncompetitive N-methyl-D-aspartate Receptor Antagonist - [EPC] (Established Pharmacologic Class)
- Uncompetitive NMDA Receptor Antagonists - [MoA] (Mechanism of Action)
- alpha-1 Adrenergic Agonist - [EPC] (Established Pharmacologic Class)
Regulatory & Marketing
Hierarchy Structure
- 50991 - Poly Pharmaceuticals, Inc.
- 50991-740 - Deconex
- 50991-740-01 - 100 TABLET in 1 BOTTLE
- 50991-740 - Deconex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50991-740). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50991-740-01 identifies a specific commercial package of 100 tablet in 1 bottle of Deconex Dmx, a human over the counter drug labeled by Poly Pharmaceuticals, Inc.. This tablet is formulated for oral use and contains dextromethorphan hydrobromide; guaifenesin; phenylephrine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Poly Pharmaceuticals, Inc. on June 01, 2019. The current certification is valid through December 31, 2026.
How is this Poly Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50991074001. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
